Skip to content
CancerIndex

Publication

Dual bispecific protein engager-armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma.

Thanida Chanpong, Nunghathai Sawasdee, Kamonlapat Supimon, Thanich Sangsuwannukul, Thaweesak Chieochansin, Seiji Okada, Pa-Thai Yenchitsomanus, Mutita Junking

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieSep 1, 2026PMID 42497585doi:10.1016/j.biopha.2026.119751 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 15, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260915-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Multiple myeloma (MM) remains an incurable plasma cell malignancy, with most patients ultimately progressing to relapsed or refractory MM (RRMM) despite therapeutic advances. Antigen heterogeneity and immune escape, particularly the loss of B-cell maturation antigen (BCMA), pose major challenges to…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.